MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E16.79 EPS (ttm)5.48 Insider Own0.10% Shs Outstand2.53B Perf Week1.39%
Market Cap233.96B Forward P/E12.55 EPS next Y7.34 Insider Trans0.00% Shs Float2.53B Perf Month6.51%
Income13.91B PEG1.38 EPS next Q1.69 Inst Own75.30% Short Float0.67% Perf Quarter20.60%
Sales53.98B P/S4.33 EPS this Y173.50% Inst Trans0.47% Short Ratio1.47 Perf Half Y11.49%
Book/sh16.17 P/B5.70 EPS next Y-0.08% ROA14.30% Target Price95.72 Perf Year21.24%
Cash/sh3.51 P/C26.21 EPS next 5Y12.17% ROE38.30% 52W Range70.89 - 94.56 Perf YTD20.16%
Dividend2.76 P/FCF38.54 EPS past 5Y28.20% ROI15.50% 52W High-2.61% Beta0.36
Dividend %3.00% Quick Ratio1.10 Sales past 5Y4.10% Gross Margin71.10% 52W Low29.91% ATR2.08
Employees68000 Current Ratio1.40 Sales Q/Q49.60% Oper. Margin28.90% RSI (14)67.60 Volatility2.23% 2.41%
OptionableYes Debt/Eq0.78 EPS Q/Q57.20% Profit Margin26.30% Rel Volume0.96 Prev Close92.10
ShortableYes LT Debt/Eq0.75 EarningsApr 28 BMO Payout47.80% Avg Volume11.58M Price92.09
Recom2.20 SMA204.33% SMA508.78% SMA20015.47% Volume11,121,552 Change-0.01%
Apr-06-22Resumed Morgan Stanley Equal-Weight $80
Dec-17-21Initiated Goldman Buy $93
Dec-16-21Initiated Daiwa Securities Neutral $70
Dec-13-21Downgrade UBS Buy → Neutral $98 → $76
Dec-09-21Initiated Wells Fargo Overweight $90
Dec-07-21Downgrade Guggenheim Buy → Neutral
Nov-29-21Downgrade Citigroup Buy → Neutral $105 → $85
Nov-19-21Initiated BMO Capital Markets Market Perform $91
Nov-01-21Upgrade Argus Hold → Buy $110
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $85
Jul-27-21Resumed Truist Buy $92
May-20-21Downgrade Argus Buy → Hold
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
May-19-22 02:47PM  
09:32AM  
09:00AM  
08:31AM  
May-18-22 10:07AM  
May-17-22 11:58AM  
May-16-22 12:46PM  
06:00AM  
May-12-22 10:00AM  
02:00AM  
May-11-22 02:28PM  
08:59AM  
May-10-22 06:45AM  
May-09-22 09:22AM  
May-06-22 09:40AM  
May-05-22 08:33PM  
May-04-22 11:39AM  
11:23AM  
06:45AM  
May-03-22 09:53AM  
May-02-22 02:16PM  
09:48AM  
06:15AM  
Apr-29-22 11:30AM  
10:32AM  
09:34AM  
06:45AM  
06:30AM  
Apr-28-22 05:21PM  
04:26PM  
03:33PM  
12:30PM  
12:08PM  
11:34AM  
10:41AM  
10:23AM  
10:15AM  
09:41AM  
07:45AM  
07:02AM  
06:41AM  
06:30AM  
06:30AM  
Apr-27-22 05:01PM  
02:03PM  
08:40AM  
06:39AM  
Apr-26-22 06:23PM  
05:20PM  
09:31AM  
05:50AM  
Apr-25-22 06:45AM  
06:18AM  
Apr-21-22 03:01PM  
10:15AM  
Apr-20-22 05:45PM  
11:07AM  
09:58AM  
08:35AM  
06:45AM  
Apr-19-22 11:50AM  
Apr-18-22 10:55AM  
09:32AM  
06:59AM  
Apr-15-22 09:58AM  
07:33AM  
Apr-14-22 12:50PM  
06:45AM  
05:55AM  
Apr-13-22 09:27AM  
07:46AM  
Apr-12-22 11:20AM  
Apr-11-22 07:01PM  
05:45PM  
09:49AM  
07:45AM  
Apr-08-22 03:17PM  
09:28AM  
06:45AM  
Apr-07-22 10:38AM  
Apr-06-22 12:39PM  
12:17PM  
09:47AM  
09:26AM  
Apr-05-22 05:45PM  
01:07PM  
11:28AM  
11:23AM  
09:52AM  
06:45AM  
Apr-04-22 03:11PM  
12:10PM  
10:40AM  
06:45AM  
Apr-02-22 08:54AM  
Apr-01-22 04:44PM  
11:06AM  
09:48AM  
06:45AM  
06:40AM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garay ArpaSVP Human Health Global Mktg.May 04Option Exercise87.1090779,0002,368May 05 05:24 PM
Oosthuizen Johannes JacobusSVP, U.S. MarketMay 04Option Exercise87.1090779,00014,961May 05 05:27 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise87.1094982,65841,429May 05 05:19 PM
Klobuchar Michael AEVP - Chief Strategy OfficerMay 04Option Exercise87.1088577,08415,775May 05 05:07 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 04Option Exercise87.1081370,8123,943May 05 05:04 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 03Option Exercise87.6545239,6183,285May 04 05:58 PM
Litchfield CarolineEVP & CFOMay 03Option Exercise87.6577367,75327,799May 04 05:54 PM
Li Dean YExecutive VP & President, MRLMay 03Option Exercise87.6577367,75316,839May 04 05:50 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 03Option Exercise87.6542737,4279,410May 04 05:44 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise87.6590279,06040,789May 04 05:37 PM
Oosthuizen Johannes JacobusSVP, U.S. MarketMay 03Option Exercise87.6577367,75314,435May 04 05:30 PM
Klobuchar Michael AEVP - Chief Strategy OfficerMay 03Option Exercise87.6577367,75315,271May 04 04:53 PM
Garay ArpaSVP Human Health Global Mktg.May 03Option Exercise87.6577367,7531,682May 04 04:45 PM
Garay ArpaSVP Human Health Global Mktg.May 03Option Exercise87.6577367,7531,682May 04 04:44 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 01Option Exercise88.6964056,7623,053May 03 04:25 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 01Option Exercise88.6957751,1749,181May 03 04:19 PM
Li Dean YExecutive VP & President, MRLMay 01Option Exercise88.691,06194,10016,589May 03 04:21 PM
Litchfield CarolineEVP & CFOMay 01Option Exercise88.6986676,80627,453May 03 04:22 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise88.6992882,30440,205May 03 04:17 PM
Oosthuizen Johannes JacobusSVP, U.S. MarketMay 01Option Exercise88.6986676,80614,089May 03 04:16 PM
Klobuchar Michael AEVP - Chief Strategy OfficerMay 01Option Exercise88.6986676,80614,925May 03 04:13 PM
Garay ArpaSVP Human Health Global Mktg.May 01Option Exercise88.6986676,8061,156May 03 04:11 PM
Williams David MichaelEVP,Chief Info&Digital OfficerFeb 10Option Exercise76.531,20291,9897,421Feb 14 11:13 AM
FRAZIER KENNETH CExecutive ChairNov 09Option Exercise0.00663,88101,250,676Nov 10 04:06 PM
FRAZIER KENNETH CExecutive ChairNov 09Sale82.26663,88154,611,362586,795Nov 10 04:06 PM
Litchfield CarolineEVP & CFONov 04Option Exercise0.0022,683042,449Nov 05 04:22 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthNov 04Option Exercise0.0029,7820146,712Nov 05 04:24 PM
Litchfield CarolineEVP & CFONov 04Sale91.0018,3351,668,50324,114Nov 05 04:22 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthNov 04Sale90.4029,7822,692,299116,930Nov 05 04:24 PM
Karachun Rita ASr. VP Fince-Global ControllerNov 03Option Exercise0.0025,000060,799Nov 04 04:19 PM
Karachun Rita ASr. VP Fince-Global ControllerNov 03Sale88.4525,0002,211,21535,799Nov 04 04:19 PM
Clyburn FrankEVP & Pres ? Human HealthNov 01Option Exercise0.0039,7620136,857Nov 02 06:16 PM
Gerberding Julie L.EVP, Chief Patient OfficerNov 01Option Exercise0.0096,2700135,432Nov 03 04:11 PM
Gerberding Julie L.EVP, Chief Patient OfficerNov 01Sale87.9196,2708,462,68239,162Nov 03 04:11 PM
Clyburn FrankEVP & Pres ? Human HealthNov 01Sale87.8739,7623,493,87997,095Nov 02 06:16 PM
Clyburn FrankEVP & Pres ? Human HealthOct 30Option Exercise88.052,358207,62298,257Nov 02 06:16 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise88.054,715415,15627,896Nov 02 06:11 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthOct 29Option Exercise0.00135,4050252,335Nov 02 06:12 PM
Chattopadhyay SanatExe V-P & Pres. MMDOct 29Option Exercise0.0024,6190117,764Nov 02 06:14 PM
Chattopadhyay SanatExe V-P & Pres. MMDOct 29Sale87.3224,6192,149,73193,145Nov 02 06:14 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthOct 29Sale87.56135,40511,856,265116,930Nov 02 06:12 PM